Curis

Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Curis reports reduced losses, positive clinical data drive growth prospects

Curis demonstrated improved financial performance, strengthened by successful fundraising and promising clinical data, positioning the company for future growth.
While facing challenges in regulatory processes and balancing expenses, Curis remains focused on innovation and market opportunities to drive value creation.
Investors should monitor Curis' upcoming presentations and regulatory developments closely, as positive outcomes could significantly impact the company's trajectory.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LEXINGTON, Mass. , Dec. 10, 2024 /PRNewswire/ -- Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, yesterday presented data from the TakeAim Leukemia study (CA-4948-102) in relapsed/refractory (R/R) Acute Myeloid Leukemia (AML) at the 66th ASH annual meeting.

Curis Announces Additional Data from TakeAim Leukemia Study

Curis, Inc. (NASDAQ:CRIS ) Q3 2024 Earnings Conference Call November 14, 2024 8:30 AM ET Company Participants Diantha Duvall - Chief Financial Officer Jim Dentzer - President & Chief Executive Officer Jonathan Zung - Chief Development Officer Conference Call Participants Ed White - H.C. Wainwright Billal Jahangiri - Truist Securities Daniel Bronder - Cantor Sean McCutcheon - Raymond James Operator Good morning, ladies and gentlemen, and welcome to the Curis Third Quarter 2024 Business Update Call.

Curis, Inc. (CRIS) Q3 2024 Earnings Call Transcript

Curis (CRIS) came out with a quarterly loss of $1.70 per share versus the Zacks Consensus Estimate of a loss of $1.88. This compares to loss of $2.13 per share a year ago.

Curis (CRIS) Reports Q3 Loss, Tops Revenue Estimates

Management to host conference call today at 8:30 a.m. ET LEXINGTON, Mass.

Curis Provides Third Quarter 2024 Business Update

LEXINGTON, Mass. , Nov. 7, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its third quarter 2024 financial and operating results on Thursday, November 14, 2024, at 8:00 a.m.

Curis to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on November 14, 2024

LEXINGTON, Mass. , Oct. 29, 2024 /PRNewswire/ -- Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that it has entered into a definitive agreement with a combination of existing and new investors for the purchase of 2,398,414 shares of its common stock in a registered direct offering priced at-the-market under Nasdaq rules.

Curis Announces $12.1 Million Registered Direct and Concurrent Private Placement

Symposium hosted by Eric S. Winer, MD, and Grzegorz S.

Curis Announces the 3rd Annual Symposium on IRAK4 in Cancer

LEXINGTON, Mass. , Sept. 17, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that James Dentzer, President and Chief Executive Officer of Curis, will participate in a fireside chat at the 2024 Cantor Fitzgerald Global Healthcare Conference later today at 4:15 PM ET.

Curis to Participate at the Upcoming 2024 Cantor Fitzgerald Global Healthcare Conference

LEXINGTON, Mass. , Sept. 4, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that James Dentzer, President and Chief Executive Officer of Curis, will participate at the following conferences: The H.C.

Curis to Present at Upcoming Healthcare Conferences in September

Curis, Inc. (NASDAQ:CRIS ) Q2 2024 Earnings Conference Call August 1, 2024 8:30 AM ET Company Participants Diantha Duvall - Chief Financial Officer Jim Dentzer - President and CEO Jonathan Zung - Chief Development Officer Conference Call Participants Yale Jen - Laidlaw Ed White - H.C. Wainwright Soumit Roy - JonesTrading Li Watsek - Cantor Operator Good morning, ladies and gentlemen.

Curis, Inc. (CRIS) Q2 2024 Earnings Call Transcript

Curis (CRIS) came out with a quarterly loss of $2.03 per share versus the Zacks Consensus Estimate of a loss of $1.70. This compares to loss of $2.40 per share a year ago.

Curis (CRIS) Reports Q2 Loss, Tops Revenue Estimates

EC Grants ODD to emavusertib in PCNSL Management to host conference call and webcast today at 8:30 a.m. ET LEXINGTON, Mass.

Curis Provides Second Quarter 2024 Financial and Operating Update

LEXINGTON, Mass. , July 25, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its second quarter 2024 financial and operating results on Thursday, August 1, 2024, at 8:00 a.m.

Curis to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024

LEXINGTON, Mass. , July 10, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that James Dentzer, President and Chief Executive Officer of Curis, will present at the Jones Healthcare Seaside Summit 2024 on July 15, 2024 at 8:00 a.m.

Curis to Present at Upcoming Healthcare Conference in July

Curis (CRIS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

What Makes Curis (CRIS) a New Buy Stock

LEXINGTON, Mass. , July 8, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that on July 1, 2024, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 25,000 shares of Curis common stock to a new employee, with a grant date of July 1, 2024 (the "Q3 2024 Inducement Grant").

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

LEXINGTON, Mass. , May 10, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will present updated data from the TakeAim Leukemia study Tuesday, May 14, 2024, at 4:00 p.m.

Curis to Present Updated Data from the TakeAim Leukemia Study

Curis, Inc. (NASDAQ:CRIS ) Q1 2024 Earnings Conference Call May 7, 2024 8:30 AM ET Company Participants Diantha Duvall - CFO Jim Dentzer - President & CEO Robert Martell - Chief Scientific Officer Conference Call Participants Soumit Roy - JonesTrading Li Watsek - Cantor Fitzgerald Yale Jen - Laidlaw & Company Billal Jahangiri - Truist Securities Sean McCutcheon - Raymond James Operator Good morning, ladies and gentlemen, and welcome to the Curis First Quarter 2024 Business Update. At this time all lines are in listen-only mode.

Curis, Inc. (CRIS) Q1 2024 Earnings Call Transcript

Curis Provides First Quarter 2024 Business Update

LEXINGTON, Mass. , April 30, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will release its first quarter 2024 financial results on Tuesday, May 7, 2024, at 8:00 a.m.

Curis to Release First Quarter 2024 Financial Results and Hold Conference Call on May 7, 2024

Curis (CRIS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Strength Seen in Curis (CRIS): Can Its 19.5% Jump Turn into More Strength?

LEXINGTON, Mass. , April 4, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive Officer of Curis, will participate at the 23rd Annual Needham Virtual Healthcare Conference being held on April 8 - 11, 2024.

Curis to Present at Upcoming Healthcare Conferences in April

NEW YORK , April 2, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Curis, Inc. (NASDAQ: CRIS) on behalf of the company's shareholders.  The investigation seeks to determine whether Curis's directors breached their fiduciary duties in connection with recent corporate actions.

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Curis, Inc. (NASDAQ: CRIS)

Curis, Inc. (CRIS) Q4 2023 Earnings Call Transcript

Emavusertib data presented at ASH showed 3 of 5 patients achieved CR in R/R PCNSL Expansion of clinical sites in US and Europe in progress Cash runway into 2025 Management to host conference call today at 8:30 a.m. ET LEXINGTON, Mass.

News for Curis Stock (CRIS)